Total Payments
$18,328
2024 Payments
$211.99
Companies
13
Transactions
134
Medicare Patients
930
Medicare Billing
$110,838
Payment Breakdown by Category
Other$12,300 (67.1%)
Food & Beverage$3,126 (17.1%)
Travel$2,313 (12.6%)
Education$439.14 (2.4%)
Consulting$150.00 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,050 | 13 | 60.3% |
| Food and Beverage | $3,126 | 93 | 17.1% |
| Travel and Lodging | $2,313 | 19 | 12.6% |
| Honoraria | $1,250 | 1 | 6.8% |
| Education | $439.14 | 7 | 2.4% |
| Consulting Fee | $150.00 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Indivior Inc. | $16,688 | 85 | $0 (2024) |
| Hikma Pharmaceuticals USA | $420.00 | 3 | $0 (2023) |
| Alkermes, Inc. | $289.51 | 4 | $0 (2019) |
| AbbVie Inc. | $266.91 | 14 | $0 (2023) |
| US WorldMeds, LLC | $212.01 | 12 | $0 (2019) |
| Braeburn Inc. | $186.23 | 5 | $0 (2024) |
| Gilead Sciences, Inc. | $119.81 | 1 | $0 (2023) |
| Orexo US, Inc. | $70.83 | 5 | $0 (2020) |
| Lucid Diagnostics Inc. | $24.04 | 1 | $0 (2021) |
| Esperion Therapeutics, Inc. | $14.40 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $211.99 | 6 | Braeburn Inc. ($169.34) |
| 2023 | $687.20 | 12 | Hikma Pharmaceuticals USA ($420.00) |
| 2022 | $283.80 | 15 | ABBVIE INC. ($144.08) |
| 2021 | $200.17 | 10 | Indivior Inc. ($78.03) |
| 2020 | $2,318 | 6 | Indivior Inc. ($2,300) |
| 2019 | $5,523 | 36 | Indivior Inc. ($5,155) |
| 2018 | $8,460 | 38 | Indivior Inc. ($8,425) |
| 2017 | $644.05 | 11 | Indivior Inc. ($468.03) |
All Payment Transactions
134 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | Cash or cash equivalent | $116.56 | General |
| Category: Opioid Use Disorder | ||||||
| 10/22/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: OUD | ||||||
| 10/16/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Opioid Use Disorder | ||||||
| 04/09/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: OUD | ||||||
| 01/23/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: Opioid Use Disorder | ||||||
| 01/23/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $4.05 | General |
| Category: Opioid Use Disorder | ||||||
| 11/30/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: OUD | ||||||
| 09/13/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: OUD | ||||||
| 09/12/2023 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Opioid Use Disorder | ||||||
| 08/30/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: OUD | ||||||
| 06/14/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $119.81 | General |
| Category: HCV | ||||||
| 06/13/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: NEUROSCIENCE | ||||||
| 04/05/2023 | Hikma Pharmaceuticals USA | Kloxxado (Drug) | Education | In-kind items and services | $210.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 04/05/2023 | Hikma Pharmaceuticals USA | Kloxxado (Drug) | Education | In-kind items and services | $140.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 04/05/2023 | Hikma Pharmaceuticals USA | Kloxxado (Drug) | Education | In-kind items and services | $70.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 02/03/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: OUD | ||||||
| 12/01/2022 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: OUD | ||||||
| 11/21/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.65 | General |
| Category: NEUROSCIENCE | ||||||
| 10/27/2022 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: OUD | ||||||
| 09/29/2022 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: OUD | ||||||
| 09/14/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: NEUROSCIENCE | ||||||
| 08/25/2022 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: OUD | ||||||
| 07/28/2022 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: OUD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 431 | 794 | $98,729 | $45,268 |
| 2022 | 6 | 220 | 401 | $55,399 | $25,330 |
| 2021 | 6 | 203 | 360 | $68,518 | $27,098 |
| 2020 | 2 | 76 | 180 | $39,300 | $13,142 |
Total Patients
930
Total Services
1,735
Medicare Billing
$110,838
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 95 | 287 | $53,390 | $23,307 | 43.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 78 | 78 | $15,232 | $9,729 | 63.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 59 | $7,279 | $2,948 | 40.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 22 | $5,315 | $2,396 | 45.1% |
| 82075 | Measurement of alcohol level in breath specimen | Office | 2023 | 14 | 66 | $3,960 | $1,940 | 49.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 86 | 86 | $3,353 | $1,529 | 45.6% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 83 | 83 | $3,320 | $1,476 | 44.5% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 19 | 101 | $3,880 | $1,124 | 29.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,000 | $819.65 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 71 | 173 | $31,183 | $13,158 | 42.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 57 | 57 | $11,172 | $7,265 | 65.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 39 | $4,846 | $2,347 | 48.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 15 | $3,600 | $914.95 | 25.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 15 | 76 | $3,040 | $912.49 | 30.0% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 41 | 41 | $1,558 | $732.08 | 47.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 94 | 235 | $49,221 | $19,478 | 39.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 26 | 39 | $6,706 | $2,373 | 35.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 16 | 16 | $3,270 | $2,079 | 63.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 19 | $4,560 | $1,900 | 41.7% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 36 | 36 | $1,368 | $636.65 | 46.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 15 | 15 | $3,394 | $631.08 | 18.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 52 | 150 | $32,100 | $10,809 | 33.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 24 | 30 | $7,200 | $2,333 | 32.4% |
About Dr. Michael Ahmann, D.O
Dr. Michael Ahmann, D.O is a Addiction Medicine healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1720245806.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ahmann, D.O has received a total of $18,328 in payments from pharmaceutical and medical device companies, with $211.99 received in 2024. These payments were reported across 134 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($11,050).
As a Medicare-enrolled provider, Ahmann has provided services to 930 Medicare beneficiaries, totaling 1,735 services with total Medicare billing of $110,838. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Family Medicine
- Location Scottsdale, AZ
- Active Since 05/17/2008
- Last Updated 11/06/2019
- Taxonomy Code 207QA0401X
- Entity Type Individual
- NPI Number 1720245806
Products in Payments
- SUBLOCADE (Drug) $14,511
- Kloxxado (Drug) $420.00
- Lucemyra/Lofexidine (Drug) $212.01
- VRAYLAR (Drug) $202.09
- BRIXADI (Drug) $186.23
- SUBOXONE SUBLINGUAL FILM (Drug) $127.79
- VIVITROL (Drug) $124.75
- Epclusa (Drug) $119.81
- Zubsolv (Drug) $70.83
- UBRELVY (Drug) $35.87
- QULIPTA (Drug) $28.95
- Vivitrol (Drug) $14.76
- NEXLETOL (Drug) $14.40
- NEOX (Biological) $13.24
- Trintellix (Drug) $11.48
- FARXIGA (Drug) $11.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Addiction Medicine Doctors in Scottsdale
Dr. Steven Locnikar, D.o, D.O
Addiction Medicine — Payments: $6,956
Addiction Medicine $6,956
Dr. Ehab Abdallah, Md, MD
Addiction Medicine — Payments: $779.73
Addiction Medicine $779.73
Dr. Ravi Chandiramani, N.d, N.D
Addiction Medicine — Payments: $84.34
Addiction Medicine $84.34
Dr. Victor Nettey, Mb, Chb, MB, CHB
Addiction Medicine
Addiction Medicine